Cytomed Therapeutics Limited Stock Alpha and Beta Analysis
| GDTC Stock | 1.52 0.01 0.65% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CytoMed Therapeutics Limited. It also helps investors analyze the systematic and unsystematic risks associated with investing in CytoMed Therapeutics over a specified time horizon. Remember, high CytoMed Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to CytoMed Therapeutics' market risk premium analysis include:
Beta 1.71 | Alpha (0.27) | Risk 5.44 | Sharpe Ratio (0.05) | Expected Return (0.27) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out CytoMed Therapeutics Backtesting, CytoMed Therapeutics Valuation, CytoMed Therapeutics Correlation, CytoMed Therapeutics Hype Analysis, CytoMed Therapeutics Volatility, CytoMed Therapeutics History and analyze CytoMed Therapeutics Performance. CytoMed Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CytoMed Therapeutics market risk premium is the additional return an investor will receive from holding CytoMed Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CytoMed Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CytoMed Therapeutics' performance over market.| α | -0.27 | β | 1.71 |
CytoMed Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of CytoMed Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how CytoMed Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.CytoMed Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how CytoMed Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading CytoMed Therapeutics shares will generate the highest return on investment. By understating and applying CytoMed Therapeutics stock market price indicators, traders can identify CytoMed Therapeutics position entry and exit signals to maximize returns.
CytoMed Therapeutics Return and Market Media
The median price of CytoMed Therapeutics for the period between Thu, Sep 25, 2025 and Wed, Dec 24, 2025 is 1.97 with a coefficient of variation of 13.66. The daily time series for the period is distributed with a sample standard deviation of 0.27, arithmetic mean of 1.99, and mean deviation of 0.2. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | CytoMed makes cash bid for potential acquisition of TC BioPharm Limiteds relevant assets | 10/14/2025 |
2 | CytoMed Therapeutics Limited stock outlook for YEAR - 2025 Historical Comparison Reliable Intraday Trade Plans - newser.com | 10/29/2025 |
3 | Applying Wyckoff theory to CytoMed Therapeutics Limited stock - Trade Entry Report AI Enhanced Trading Alerts - newser.com | 11/05/2025 |
4 | Is CytoMed Therapeutics Limited stock a fit for income portfolios - Jobs Report Verified Chart Pattern Signals - newser.com | 11/11/2025 |
5 | Why CytoMed Therapeutics Limited stock could benefit from AI revolution - Market Sentiment Summary Risk Controlled Daily Trade Plans - Fundao Cultural do Par | 11/14/2025 |
6 | Is CytoMed Therapeutics Limited stock vulnerable to regulatory risks - Bond Market Real-Time Stock Entry Alerts - newser.com | 11/17/2025 |
7 | Can CytoMed Therapeutics Limited stock resist broad market declines - Gold Moves Real-Time Chart Breakout Alerts - newser.com | 11/20/2025 |
8 | 12 Health Care Stocks Moving In Tuesdays Pre-Market Session | 12/09/2025 |
9 | Why CytoMed Therapeutics Limited stock could outperform in 2025 - Analyst Downgrade Daily Chart Pattern Signals - DonanmHaber | 12/19/2025 |
About CytoMed Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CytoMed or other stocks. Alpha measures the amount that position in CytoMed Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Days Sales Outstanding | 86.87 | 77.22 | PTB Ratio | 5.98 | 5.68 |
CytoMed Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of CytoMed Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CytoMed Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of CytoMed Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of CytoMed Therapeutics. Please utilize our Beneish M Score to check the likelihood of CytoMed Therapeutics' management manipulating its earnings.
| 6th of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with CytoMed Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out CytoMed Therapeutics Backtesting, CytoMed Therapeutics Valuation, CytoMed Therapeutics Correlation, CytoMed Therapeutics Hype Analysis, CytoMed Therapeutics Volatility, CytoMed Therapeutics History and analyze CytoMed Therapeutics Performance. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
CytoMed Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.